Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 20-28

  Kodama, Itsuo ^a   Kamiya, Kaichiro ^a   Toyama, Junji ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DEETHYLAMIODARONE; DRUG METABOLITE; ION CHANNEL; LIOTHYRONINE; MESSENGER RNA;

ANTIARRHYTHMIC ACTIVITY; CALCIUM CURRENT; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG MECHANISM; ELECTRIC POTENTIAL; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE POTENTIAL; HYPOTHYROIDISM; ION CURRENT; MAMMAL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; RAT; SODIUM CURRENT;

EID: 0032745315     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00698-0     Document Type: Conference Paper

References (85)

1. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction . N Engl J Med. 321:1989;406-412.
2. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
3. Ahmed R., Singh B.N. Antiarrhythmic drugs. Curr Opin Cardiol. 8:1993;10-21.
4. Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., Chalmers T.C. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion a meta-analysis of randomized control trials . Circulation. 82:1990;1106-1116.
5. Hallstrom A.P., Cobb L.A., Yu B.H., Weaver W.D., Fahrenbruch C.E. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 68:1991;1025-1031.
6. Morganroth J., Goin J.E. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias a meta-analysis . Circulation. 84:1991;1977-1983.
7. Singh B.N. Controlling cardiac arrhythmias by lengthening repolarization historical overview . Am J Cardiol. 72:(suppl):1993;18F-24F.
8. Singh B.N. Expanding indications for the use of Class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 6:1995;887-900.
9. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, SWORD Investigators. Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial. (Abstr.) J Am Coll Cardiol 1995;February:15A.
10. Link M.S., Homoud M., Foote C.B., Wang P.J., Estes N.A.M. III. Antiarrhythmic drug therapy for ventricular arrhythmias current perspectives . J Cardiovasc Electrophysiol. 7:1996;653-670.
11. Antiarrhythmic Therapy A Pathophysiological Approach . 1994;Futura Publishing Company, Armonk, NY.
12. Anderson J.L. Contemporary clinical trials in ventricular tachycardia and fibrillation implications of ESVEM, CASCADE, and CASH for clinical management . J Cardiovasc Electrophysiol. 6:1995;880-886.
13. Nademanee K., Singh B.N., Stevenson W.G., Weiss J.N. Amiodarone and post-MI patients. Circulation. 88:1993;764-774.
14. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual data from 6500 patients in randomised trials . Lancet. 350:1997;1417-1424.
15. Sim I., McDonald M., Lavori P.W., Norbutas C.M., Hlatky M.A. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation. 96:1997;2823-2829.
16. Singh B.N. Amiodarone historical development and pharmacologic profile . Am Heart J. 106:1983;788-797.
17. Zipes D.P., Prystowsky E.N., Heger J.J. Amiodarone electrophysiologic actions, pharmacokinetics and clinical effects . J Am Coll Cardiol. 3:1984;1059-1071.
18. Kodama I., Kamiya K., Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 35:1997;13-29.
19. Mason J.W. Amiodarone. N Engl J Med. 316:1987;455-466.
20. Nattel S., Talajic M., Fermini B., Roy D. Amiodarone pharmacology, clinical actions, and relationships between them . J Cardiovasc Electrophysiol. 3:1992;266-280.
21. Kennedy R.L., Griffiths H., Gray T.A. Amiodarone and the thyroid. Clin Chem. 35:1989;1882-1887.
22. Singh B.N., Venkatesh N., Nademanee K., Josephson M.A., Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis. 31:1989;249-280.
23. Matsumori A., Ono K., Nishio R., Nose Y., Sasayama S. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells a possible mechanism for its effect in heart failure . Circulation. 96:1997;1386-1389.
24. Mason J.W., Hondeghem L.M., Katzung B.G. Amiodarone blocks inactivated cardiac sodium channels. Pflügers Arch. 396:1983;79-81.
25. Mason J.W., Hondeghem L.M., Katzung B.G. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res. 55:1984;277-285.
26. max of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone. Br J Pharmacol. 92:1987;97-103.
27. max in cardiac Purkinje and ventricular muscle fibers. Eur J Pharmacol. 112:1985;419-422.
28. max of action potential in single ventricular myocytes. Br J Pharmacol. 102:1991;651-656.
29. Kamiya K., Cheng J., Kodama I., Toyama J. Acute and chronic effects of amiodarone on action potential and ionic currents in single rabbit ventricular myocytes. Toyama J., Hiraoka M., Kodama I. Recent Progress in Electropharmacology of the Heart. 1995;139-149 CRC Press, Boca Raton.
30. Kodama I., Suzuki R., Kamiya K., Iwata H., Toyama J. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol. 107:1992;502-509.
31. max of action potential in single ventricular myocytes. J Mol Cell Cardiol. 22:1990;1-12.
32. Follmer C.H., Aomine M., Yeh J.Z., Singer D.H. Amiodarone-induced block of sodium current in isolated cardiac cells. J Pharmacol Exp Ther. 243:1987;187-194.
33. + channels by antiarrhythmic drugs the effect of amiodarone, propafenone and diprafenone . J Membrane Biol. 102:1988;105-119.
34. Sheldon R.S., Hill R.J., Cannon N.J., Duff H.J. Amiodarone biochemical evidence for binding to a receptor for Class I drugs associated with the rat cardiac sodium channel . Circ Res. 65:1989;477-482.
35. Nishimura M., Follmer C.H., Singer D.H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 251:1989;650-659.
36. Valenzuela C., Bennett P.B. Voltage- and use-dependent modulation of calcium channel current in guinea pig ventricular cells by amiodarone and des-oxo-amiodarone. J Cardiovasc Pharmacol. 17:1991;894-902.
37. Varro A., Virag L., Papp J.G. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol. 117:1996;1181-1186.
38. Wagner J.A., Weisman H.F., Levine J.H., Snowman A.M., Snyder S.H. Differential effects of amiodarone and desethylamiodarone on calcium antagonist receptors. J Cardiovasc Pharmacol. 15:1990;501-507.
39. Balser J.R., Bennett P.B., Hondeghem L.M., Roden D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes actions of quinidine and amiodarone . Circ Res. 69:1991;519-529.
40. + current differential sensitivity to block by class III antiarrhythmic agents . J Gen Physiol. 96:1990;195-215.
41. Ks) on the delayed rectifier potassium current in rabbit ventricular myocytes. (Abstr.) Circulation. 98:1998;SI373.
42. + channel activities of cultured rat cardiomyocytes. J Mol Cell Cardiol. 29:1997;617-627.
43. Sato R., Koumi S., Singer D.H., Hisatome I., Jia H., Eager S., Wasserstrom J.A. Amiodarone blocks the inward rectifier potassium channel in isolated guinea pig ventricular cells. J Pharmacol Exp Ther. 269:1994;1213-1219.
44. + channels in guinea-pig ventricular cells. Br J Pharmacol. 119:1996;133-141.
45. Watanabe Y., Hara Y., Tamagawa M., Nakaya H. Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells. J Pharmacol Exp Ther. 279:1996;617-624.
46. ATP) channels but retards hypoxic or ischemic myocardial contracture. (Abstr.) Jpn J Pharmacol 1997;73:S-1,45.
47. + Channels in Cardiovascular Medicine. 1993;53-68 Springer-Verlag, Paris.
48. Anderson K.P., Walker R., Dustman T., Lux R.L., Ershler P.R., Kates R.E., Urie P.M. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation. 79:1989;948-958.
49. Ikeda N., Nademanee K., Kannan R., Singh B.N. Electrophysiologic effects of amiodarone experimental and clinical observation relative to serum and tissue drug concentrations . Am Heart J. 108:1984;890-898.
50. Kato R., Venkatesh N., Kamiya K., Yabek S., Kannan R., Singh B.N. Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone comparison with amiodarone during chronic administration in rabbits . Am Heart J. 115:1988;351-359.
51. Singh B.N., Vaughan Williams E.M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
52. Venkatesh N., Somani P., Bersohn M., Phair R., Kato R., Singh B.N. Electropharmacology of amiodarone absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations . Am Heart J. 112:1986;916-922.
53. Kodama I., Kamiya K., Honjo H., Toyama J. Acute and chronic effects of amiodarone on mammalian ventricular cells. Jpn Heart J. 37:1996;719-730.
54. Kamiya K., Cheng J., Kodama I., Toyama J. Modulation of repolarizing potassium channels and Kv1.5 mRNA by long-term treatment with amiodarone. (Abstr.) Circulation. 92:1995;SI373.
55. Peele M.E. Transcriptional regulation of rat Kv1.5 potassium channel gene by amiodarone and thyroid hormone. (Abstr.) Circulation. 92:1995;SI373.
56. Nattel S., Davies M., Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation. 77:1988;200-208.
57. Nattel S., Talajic M., Quantz M., DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials evidence for calcium channel-blocking activity . Circulation. 76:1987;442-449.
58. Yabek S.M., Kato R., Singh B.N. Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol. 8:1986;197-207.
59. Nattel S. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. J Cardiovasc Pharmacol. 8:1986;771-777.
60. Talajic M., DeRoode M.R., Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs evidence for clinically relevant activity of the metabolite . Circulation. 75:1987;265-271.
61. Singh B.N., Nademanee K. Amiodarone and thyroid function clinical implications during antiarrhythmic therapy . Am Heart J. 106:1983;857-868.
62. Yin Y.L., Perret G.Y., Nicolas P., Vassy R., Uzzan B., Tod M. In vivo effects of amiodarone on cardiac β-adrenoceptor density and heart rate require thyroid hormones. J Cardiovasc Pharmacol. 19:1992;541-545.
63. 3 and amiodarone on the contractility and the density of β-adrenoceptors of chicken cardiac myocytes. Eur J Pharmacol. 261:1994;97-104.
64. Patterson E., Walden K.M., Khazaeli M.B., Montgomery D.G., Lucchesi B.R. Cardiac electrophysiologic effects of acute and chronic amiodarone administration in the isolated perfused rabbit heart altered thyroid hormone metabolism . J Pharmacol Exp Ther. 239:1986;179-184.
65. Lambert C., Cardinal R., Vermeulen M., Lamontagne D., Nadeau R., Paradis P., Rouleau J.L. Lack of relation between the ventricular refractory period prolongation by amiodarone and the thyroid state in rats. J Pharm Exp Ther. 242:1987;320-325.
66. Polikar R., Goy J.J., Schlapfer J., Lemarchand-Beraud T., Biollaz J., Magnenat P., Nicod P. Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes. Am J Cardiol. 58:1986;987-991.
67. Bosch R.F., Li G.R., Gaspo R., Nattel S. Ionic mechanisms of electrophysiologic effects of chronic amiodarone therapy and hypothyroidism Does amiodarone act via cardiac hypothyroidism? (Abstr.) Circulation. 94:1996;SI161.
68. Aanderaud S., Sundsfjord J., Aarbokke J. Amiodarone inhibits the conversion of thyroxin to triiodothyronine in isolated rat hepatocytes. Endocrinology. 115:1984;1605-1608.
69. 3 levels during amiodarone treatment a potential method for monitoring chronic drug therapy . Circulation. 66:1982;202-211.
70. Kaptein E.M., Egodage P.M., Hoopes M.T., Burger A.G. Amiodarone alters thyroxin transfer and distribution in humans. Metabolism. 37:1988;1107-1113.
71. 3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. FEBS Lett. 140:1982;229-233.
72. Franklyn J.A., Davis J.R., Gammage M.D., Littler W.A., Ramsden D.B., Sheppard M.C. Amiodarone and thyroid hormone action. Clin Endocrinol. 22:1985;257-264.
73. Latham K.R., Sellitti D.F., Goldstein R.E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J Am Coll Cardiol. 9:1987;872-876.
74. Hodin R.A., Lazar M.A., Chin W.W. Differential and tissue specific regulation of multiple rat c-erbA messenger RNA species by thyroid hormone. J Clin Invest. 85:1990;101-105.
75. 1-receptor protein. Endocrinology. 134:1994;1665-1670.
76. 1, whereas disopyramide, lignocaine, propafenone, metoprolol, d,l-sotalol, and verapamil have no inhibitory effect. J Cardiovasc Pharmacol. 26:1995;222-226.
77. 1-receptor protein. Mol Cell Endocrinol. 112:1995;15-19.
78. Lindenmeyer M., Sporri S., Staubli M., Studer A., Studer H. Does amiodarone affect heart rate by inhibiting the intracellular generation of triiodothyronine from thyroxine? Br J Pharmacol. 82:1984;275-280.
79. Staubli M., Studer H. The effects of amiodarone on the electrocardiogram of the guinea-pig are not explained by interaction with thyroid hormone metabolism alone. Br J Pharmacol. 88:1986;405-410.
80. Kodama I, Honjo H, Osaka T, Kamiya K, Iwata H, Toyama J. Effects of amiodarone and bepridil on ventricular depolarization and repolarization. In: Hashiba K, Moss AJ, Schwartz PJ, eds. QT Prolongation and Ventricular Arrhythmias. Ann NY Acad Sci 1992;644:210-222.
81. Finance O., Manning A., Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, d,l-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol. 26:1995;570-576.
82. Manning A., Thisse V., Hodeige D., Richard J., Heyndrickx J.P., Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent electrophysiological effects in anesthetized dogs . J Cardiovasc Pharmacol. 25:1995;252-261.
83. Manning A.S., Bruyninckx C., Ramboux J., Chatelain P. SR 33589, a new amiodarone-like agent effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats . J Cardiovasc Pharmacol. 26:1995;453-461.
84. Raatikainen M.J.P., Napolitano C.A., Druzgala P., Dennis D.M. Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J Pharmacol Exp Ther. 277:1996;1454-1463.
85. + current. Circulation. 96:1997;3696-3703.